Tumor-Specific T Cell Activation in Malignant Brain Tumors

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2020 Mar 3

PMID 32117316

Citations 30

Authors

Malte Mohme

Marian Christoph Neidert

Affiliations

Soon will be listed here.

Abstract

Due to their delicate locations as well as aggressive and infiltrative behavior, malignant brain tumors remain a therapeutic challenge. Harnessing the efficacy and specificity of the T-cell response to counteract malignant brain tumor progression and recurrence, represents an attractive treatment option. With the tremendous advances in the current era of immunotherapy, ongoing studies aim to determine the best treatment strategies for mounting a tumor-specific immune response against malignant brain tumors. However, immunosuppression in the local tumor environment, molecular and cellular heterogeneity as well as a lack of suitable targets for tumor-specific vaccination impede the successful implementation of immunotherapeutic treatment strategies in neuro-oncology. In this review, we therefore discuss the role of T cell exhaustion, the genetic and antigenic landscape, potential pitfalls and ongoing efforts to overcome the individual challenges in order to elicit a tumor-specific T cell response.

Citing Articles

Comprehensive causal analysis between autoimmune diseases and glioma: A Mendelian randomization study.

Deng N, Agila R, He Q, You C, Zheng S Medicine (Baltimore). 2025; 104(10):e41815.

PMID: 40068088 PMC: 11902947. DOI: 10.1097/MD.0000000000041815.

Murine Regulatory CD4 T Cells Are Increased in Leukemic Spleens and Show High Co-Expression of Co-Regulatory Molecules CD39, CD73, PD1, and TIGIT.

Kruger J, Wellbrock J, Witt M, Kruppa N, Muschhammer J, Bokemeyer C Int J Mol Sci. 2024; 25(21).

PMID: 39518969 PMC: 11546357. DOI: 10.3390/ijms252111412.

Transcriptomics-based characterization of the immuno-stromal microenvironment in pediatric low-grade glioma.

Korner M, Spohn M, Schuller U, Bockmayr M Oncoimmunology. 2024; 13(1):2386789.

PMID: 39135890 PMC: 11318680. DOI: 10.1080/2162402X.2024.2386789.

Current approaches in glioblastoma multiforme immunotherapy.

Aghajani M, Jalilzadeh N, Aghebati-Maleki A, Yari A, Tabnak P, Mardi A Clin Transl Oncol. 2024; 26(7):1584-1612.

PMID: 38512448 DOI: 10.1007/s12094-024-03395-7.

Role of Serotonergic System in Regulating Brain Tumor-Associated Neuroinflammatory Responses.

Karmakar S, Lal G Methods Mol Biol. 2024; 2761:181-207.

PMID: 38427238 DOI: 10.1007/978-1-0716-3662-6_14.

References

Harada M, Li Y, Ohnmacht G, Rosenberg S, Robbins P . Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. J Immunother. 2001; 24(4):323-33. DOI: 10.1097/00002371-200107000-00008. View

Rapp C, Warta R, Stamova S, Nowrouzi A, Geisenberger C, Gal Z . Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. Acta Neuropathol. 2017; 134(2):297-316. DOI: 10.1007/s00401-017-1702-1. View

Bassani-Sternberg M, Pletscher-Frankild S, Jensen L, Mann M . Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics. 2015; 14(3):658-73. PMC: 4349985. DOI: 10.1074/mcp.M114.042812. View

Zappasodi R, Merghoub T, Wolchok J . Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell. 2018; 33(4):581-598. PMC: 5896787. DOI: 10.1016/j.ccell.2018.03.005. View

Westphal M, Lamszus K . The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci. 2011; 12(9):495-508. DOI: 10.1038/nrn3060. View

Abou-El-Ardat K, Seifert M, Becker K, Eisenreich S, Lehmann M, Hackmann K . Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas. Neuro Oncol. 2017; 19(4):546-557. PMC: 5464316. DOI: 10.1093/neuonc/now231. View

Bao L, Dunham K, Lucas K . MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother. 2011; 60(9):1299-307. PMC: 11029270. DOI: 10.1007/s00262-011-1037-z. View

Ladomersky E, Zhai L, Lenzen A, Lauing K, Qian J, Scholtens D . IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018; 24(11):2559-2573. PMC: 5984675. DOI: 10.1158/1078-0432.CCR-17-3573. View

Carreno B, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti A . Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015; 348(6236):803-8. PMC: 4549796. DOI: 10.1126/science.aaa3828. View

10.

Weinzierl A, Lemmel C, Schoor O, Muller M, Kruger T, Wernet D . Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics. 2006; 6(1):102-13. DOI: 10.1074/mcp.M600310-MCP200. View

11.

Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R . Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res. 2011; 17(13):4296-308. DOI: 10.1158/1078-0432.CCR-10-2557. View

12.

Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li G . Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology. 2016; 5(11):e1196310. PMC: 5139638. DOI: 10.1080/2162402X.2016.1196310. View

13.

Patel M, Kim J, Theodros D, Tam A, Velarde E, Kochel C . Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J Immunother Cancer. 2016; 4:28. PMC: 4869343. DOI: 10.1186/s40425-016-0132-2. View

14.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

15.

Rossjohn J, Gras S, Miles J, Turner S, Godfrey D, McCluskey J . T cell antigen receptor recognition of antigen-presenting molecules. Annu Rev Immunol. 2014; 33:169-200. DOI: 10.1146/annurev-immunol-032414-112334. View

16.

Kim J, Patel M, Mangraviti A, Kim E, Theodros D, Velarde E . Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clin Cancer Res. 2016; 23(1):124-136. PMC: 5735836. DOI: 10.1158/1078-0432.CCR-15-1535. View

17.

Yang I, Tihan T, Han S, Wrensch M, Wiencke J, Sughrue M . CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci. 2010; 17(11):1381-5. PMC: 3064460. DOI: 10.1016/j.jocn.2010.03.031. View

18.

Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber S . T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res. 2018; 24(17):4175-4186. PMC: 6081269. DOI: 10.1158/1078-0432.CCR-17-1846. View

19.

Kmiecik J, Poli A, Brons N, Waha A, Eide G, Enger P . Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. 2013; 264(1-2):71-83. DOI: 10.1016/j.jneuroim.2013.08.013. View

20.

Du Z, Abedalthagafi M, Aizer A, Mchenry A, Sun H, Bray M . Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015; 6(7):4704-16. PMC: 4467109. DOI: 10.18632/oncotarget.3082. View